3
Bambusa Therapeutics, Inc.
- Report period
- 29 Oct 2026
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 29 Oct 2026, 16:27
- Role
- Co-Founder and Chief Development Officer; Exhibit 24 - Power of Attorney
- Next action
- Open filing details